AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
51.40
-0.80 (-1.53%)
Apr 2, 2025, 12:40 PM CST
-14.90%
Market Cap 4.40B
Revenue (ttm) 32.25M
Net Income (ttm) -447.49M
Shares Out 84.99M
EPS (ttm) -6.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,000
Average Volume 29,363
Open 51.40
Previous Close 52.20
Day's Range 51.40 - 51.40
52-Week Range 48.85 - 61.90
Beta n/a
RSI 33.96
Earnings Date Mar 20, 2025

About AP Biosciences

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.